Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.
Type:
Grant
Filed:
May 26, 2000
Date of Patent:
May 24, 2005
Assignees:
Curis, Inc., Biogen Idec Inc.
Inventors:
R. Blake Pepinsky, Chenhui Zeng, Darren P. Baker, Dingyi Wen, Kevin P. Williams, Ellen A. Garber, Kathryn L. Strauch, Frederick R. Taylor, Paul H. Weinreb, Russell C. Petter, Alphonse Galdes, Jeffrey Porter
Abstract: The present application is directed to the discovery that hedgehog gene products are able to protect peripheral nerve cells under conditions which otherwise result in peripheral neuropathy. Certain aspects of the invention are directed to preparations of hedgehog polypeptides, or other molecules which regulate patched or smoothened signalling, and their uses as protective agents against both acquired and hereditary neuropathies. As used herein, “peripheral neuropathy” refers to a disorder affecting a segment of the peripheral nervous system. For instance, the method of the present invention can be used as part of a treatment program in the management of neuropathies associated with systemic disease, e.g., viral infections, diabetes, inflamation; as well as genetically acquired (hereditary) neuropathies, e.g., Charcot-Marie-Tooth disease; and neuropathies caused by a toxic agent, e.g., a chemotherapeutic agent such as vincristine.
Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function by contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize hedgehog activity.
Abstract: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-?superfamily of proteins.
Type:
Grant
Filed:
May 6, 1997
Date of Patent:
March 1, 2005
Assignee:
Curis, Inc.
Inventors:
Charles M. Cohen, Kuber T. Sampath, Slobodon Vukicevic
Abstract: The present invention provides methods of identifying and/or characterizing agents that promote differentiation of stem cells to a particular differentiated cell type. The invention further provides methods of treating injuries and degenerative diseases by administering agents that promote the differentiation of stem cells to particular differentiated cell types.
Type:
Application
Filed:
June 4, 2004
Publication date:
January 27, 2005
Applicant:
Curis, Inc.
Inventors:
Lee Rubin, Karen Kotkow, Cheng-Jung Lai
Abstract: The present invention makes available methods and reagents for inducing activation of a hedgehog pathway in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as a small molecule, in a sufficient amount to achieve a therapeutic result. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.
Type:
Application
Filed:
December 9, 2003
Publication date:
January 20, 2005
Applicant:
Curis, Inc.
Inventors:
Anthony Baxter, Edward Boyd, Oivin Guicherit, Jeffrey Porter, Stephen Price, Lee Rubin
Abstract: Disclosed are methods and compositions for identifying compounds having an ability to modulate expression of a morphogen, particularly OP-1, OP-1 homologues and closely related proteins, using one or more OP-1-specific, non-coding sequences and a suitable reporter gene. In preferred embodiments, the OP-1-specific non-coding DNA sequence comprises a Pax-responsive OP-1-modulating element.
Type:
Grant
Filed:
May 15, 2001
Date of Patent:
December 7, 2004
Assignee:
Curis, Inc.
Inventors:
Dorai Haimanti, Herman Oppermann, Kuber T. Sampath, Alyssa A. Shepard
Abstract: One aspect of the present application relates to a method for limiting damage to neuronal cells by ischemic or epoxic conditions, e.g., such as may be manifest by a reduction in brain infarct volume, by administering to an individual a hedgehog therapeutic or ptc therapeutic in an amount effective for reducing cerebral infarct volume.
Abstract: The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.
Abstract: A hedgehog conjugate which is characterized in that it contains: a) a polypeptide composed of 10 to 30 hydrophobic amino acids and/or amino acids which form transmembrane helices and are positively charged, b) 1 to 4 aliphatic, saturated or unsaturated hydrocarbon residues with a chain length of 10 to 24 C atoms and with a hydrophobic action or c) a hydrophobic thio compound covalently bound to a hedgehog protein and which has a several-fold increased activity and is suitable as a pharmaceutical agent.
Type:
Grant
Filed:
October 21, 2002
Date of Patent:
November 16, 2004
Assignee:
Curis, Inc.
Inventors:
Angelika Esswein, Kurt Lang, Petra Rueger, Tilman Seytter
Abstract: It is shown here that hedgehog polypeptides possess novel activities beyond phenotype specification. Using cultures derived from the embryonic day 14.5 (E14.5) rat ventral mesencephalon, we show that hedgehog is also trophic for dopaminergic neurons and other neurons which are sensitive to exotoxicity.
Type:
Application
Filed:
September 18, 2003
Publication date:
November 4, 2004
Applicant:
Curis, Inc.
Inventors:
Alphonse Galdes, Nagesh Mahanthappa, Thomas Engber
Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.
Type:
Grant
Filed:
June 16, 1994
Date of Patent:
October 5, 2004
Assignee:
Curis, Inc.
Inventors:
David C. Rueger, Thangavel Kuberasampath, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen
Abstract: One aspect of the present application relates to a method for limiting damage to neuronal cells by ischemic or epoxic conditions, e.g., such as may be manifest by a reduction in brain infarct volume, by administering to an individual a hedgehog therapeutic or ptc therapeutic in an amount effective for reducing cerebral infarct volume.
Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating the consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.
Abstract: Disclosed are 1) amino acid sequence data, structural features, homologies and various other data characterizing morphogenic proteins, 2) methods of producing these proteins from natural and recombinant sources and from synthetic constructs, 3) morphogenic devices comprising these morphogenic proteins and a suitably modified tissue-specific matrix, and 4) methods of inducing non-chondrogenic tissue growth in a mammal.
Type:
Application
Filed:
March 10, 2003
Publication date:
May 27, 2004
Applicant:
Curis, Inc.
Inventors:
Charles M. Cohen, Kuber T. Sampath, Roy H. L. Pang, Hermann Oppermann, David C. Rueger
Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.
Type:
Grant
Filed:
September 25, 1997
Date of Patent:
April 20, 2004
Assignee:
Curis, Inc.
Inventors:
David C. Rueger, Kuber T. Sampath, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen
Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
Type:
Application
Filed:
April 4, 2003
Publication date:
February 5, 2004
Applicant:
Curis, Inc.
Inventors:
Anthony David Baxter, Edward Andrew Boyd, Oivin Guicherit, Stephen Price, Lee L. Rubin
Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating to consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.